Adverse reaction: apnoea and hypoglycaemia Number of events · neonates receiving EBT
1 finding from 1 review
Change in disability score · children with SMA types II and III
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Muscle strength · children with SMA types II and III
1 finding from 1 review
no estimate extracted
1 study · 9 participants
Very low
Acquiring the ability to stand or walk · children with SMA types II and III
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in quality of life · children with SMA types II and III
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in pulmonary function · children with SMA types II and III
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time from birth until death or full‐time ventilation · children with SMA types II and III
1 finding from 1 review
no estimate extracted
1 study · 9 participants
Low
Adverse events related to treatment · children with SMA types II and III
1 finding from 1 review
no estimate extracted
1 study · 9 participants
Very low
Severe PPH (≥ 1000 mL) · women in the third stage of labour
Intravenous/intramuscular ergot alkaloids may leads to lower estimated or measured blood loss of at least 1000 mL visual estimation compared with no uterotonic agents (low certainty).
1 finding from 1 review
Haemoglobin (g/dL) · women in the third stage of labour
1 finding from 1 review
Use of therapeutic uterotonics · women in the third stage of labour
Intravenous/intramuscular ergot alkaloids may leads to lower use of therapeutic uterotonics compared with no uterotonic agents (low certainty).
1 finding from 1 review
Elevation of blood pressure · women in the third stage of labour
Intravenous/intramuscular ergot alkaloids may leads to higher elevation of blood pressure compared with no uterotonic agents (low certainty).
1 finding from 1 review
Pain after birth requiring analgesia (not prespecified) · women in the third stage of labour
Intravenous/intramuscular ergot alkaloids probably leads to higher pain after birth requiring analgesia (not prespecified) compared with no uterotonic agents (moderate certainty).
1 finding from 1 review
Mean blood loss (mL) visual estimation · women in the third stage of labour
1 finding from 1 review
Maternal blood loss of 500 mL or greater · women in the third stage of labour
Intravenous/intramuscular ergot alkaloids may leads to lower estimated or measured blood loss of at least 500 mL visual estimation compared with no uterotonic agents (low certainty).
1 finding from 1 review
Seizure cessation: within 10 minutes · Children with acute tonic‐clonic seizures
Summary of findings ‐ Intravenous lorazepam showed no clear difference in seizure cessation: within 10 minutes compared with intranasal lorazepam (moderate certainty).
1 finding from 1 review
Time from drug administration to stopping of seizures · Children with acute tonic‐clonic seizures
1 finding from 1 review
Incidence of respiratory depression · Children with acute tonic‐clonic seizures
1 finding from 1 review
Additional drugs required to stop the seizure · Children with acute tonic‐clonic seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Seizure recurrence within 24 hours · Children with acute tonic‐clonic seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found